ERRATUM

BMC Cancer





Erratum to: KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models

Giovanni Luca Gravina¹, Andrea Mancini¹, Patrizia Sanita¹, Flora Vitale¹, Francesco Marampon¹, Luca Ventura², Yosef Landesman³, Dilara McCauley³, Michael Kauffman³, Sharon Shacham³ and Claudio Festuccia^{1*}

Unfortunately, the original version of this article [1] contained a mistake. The word 'survivin' in the title was incorrectly included as 'surviving'. The title has been corrected above and in the original article.

Author details

¹Department of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L'Aquila, L'Aquila, Italy. ²Pathology Division, San, Salvatore Hospital, L'Aquila, Italy. ³Karyopharm Therapeutics, Newton, MA, USA.

Received: 21 December 2015 Accepted: 21 December 2015 Published online: 11 January 2016

Reference

 Gravina G, Mancini A, Sanita P, Vitale F, Marampon F, Ventura L. KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models. BMC Cancer. 2015;15:941.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit



Radiobiology, University of L'Aquila, L'Aquila, Italy Full list of author information is available at the end of the article

¹Department of Biotechnological and Applied Clinical Sciences, Laboratory of

* Correspondence: claudio.festuccia@univaq.it



© 2016 Gravina et al. **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.